# A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

> **NCT05303467** · PHASE1 · RECRUITING · sponsor: **Boston Scientific Corporation** · enrollment: 36 (estimated)

## Conditions studied

- Glioblastoma Multiforme
- Recurrent Glioblastoma

## Interventions

- **DEVICE:** TheraSphere GBM

## Key facts

- **NCT ID:** NCT05303467
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-30
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05303467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05303467, "A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05303467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*